Cancer of ColonNCT04773626
Tumor Deposits in Cancer Colon
An observational study of Cancer of Colon, run by Assiut University.
Trial summary
1. Assessment of correlation between tumor deposits and clinicopathological characteristics of colorectal cancer. 2. Detection of association between tumor deposits and stage of colorectal cancer. 3. Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer of Colon
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jun 2021to Apr 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: 1. This retrospective study includes primary invasive colorectal carcinoma samples from Egyptian patients that will be retrieved from the registry of Pathology department, South Egypt Cancer Institute and Assiut University Hospital. 2. All patients who underwent resection of colorectal cancer will be included in our study.
Who may be able to join
- 1-This retrospective study includes primary invasive colorectal carcinoma samples from Egyptian patients.
- 2-Patients who underwent resection of colorectal cancer will be included in our study.
Who cannot join
- 1-All patients who underwent endoscopic biopsies
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Evaluation of the Role of Tumor Deposits on the Prognosis of Colorectal Carcinoma
- Assessment of correlation between tumor deposits and clinicopathological characteristics of colorectal cancer.
- Detection of association between tumor deposits and stage of colorectal cancer.
- Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.
Read the detailed description
Colorectal cancer remains the third most common cancer and the third leading cause of cancer-related deaths. For colon cancer alone, 101,220 new cases were projected to occur in 2019, causing51,020 deaths.
A number of risk factors have been identified that influence susceptibility to colorectal cancer, including a family history, the presence of adenomatous polyps, inflammatory bowel disease (ulcerative colitis or Crohn's disease), and number of environmental factors of which diet is the most significant.
CRC differs from many other cancers in that diagnosis of the disease can be made earlier by screening techniques including colonoscopy. The progression of CRC is well established and begins with hyperproliferation of the colonic mucosa and adenoma formation and then adenocarcinomas that vary in metastatic potential.
The progression from normal intestinal epithelium to an invasive carcinoma is estimated to take 7-12 years. With the advent of early screening measures developed over the last few decades, CRC has become a preventable disease by treating patients with adenomatous polyps. Nearly 50% of patients diagnosed with CRC develop metastasis within five years. Most commonly these tumors metastasize to the liver and lungs but may be discovered in many other sites.
Despite significant improvements in both prevention and screening over the last twenty years, about 36,500 (36%) of such cases are still being diagnosed in stage III, with regional lymph node involvement (LN+, N1a-b, N2a-b) or tumor deposits (TD+, N1c).
Tumor deposits (TDs) or mesenteric tumor satellites were firs described in rectal carcinoma by Gabriel et al at St. Mark's Hospital in 1935. Subsequently, TDs have been detected in various malignancies other than colorectal carcinoma, including gastric, pancreatic, gallbladder, and bile duct carcinomas . Over the years, there is much debate about the genesis, histopathologic characteristics, and prognostic value of TDs.
TDs are associated with advanced colorectal carcinoma stage and poor prognosis, with variable outcome due to different definitions of TDs.
Before the 5th edition, published in 1997, TNM classification did not consider microscopic TDs to be lymph node metastases (LNMs), and they classified them as discontinuous extension in the T category .
In the 5th TNM edition the 3-mm rule was introduced, which stated that TDs >3mm in diameter were LNMs .
In the 6th edition published in 2002, TDs were classified based on the contour of the deposit. A TD with a smooth contour was considered as LMN, whereas a TD with an irregular contour was considered as venous invasion (V1/2) or lymphatic invasion (L1).
The 8th TNM Edition clarified that the presence of TDs does not change the primary tumor T category, but changes the node status (N) to pN1c if all regional lymph nodes are negative on pathological examination.
In studies of rectal cancer patients, it should be taken into account that TDs may indicate microscopic residuals of the main tumor after neoadjuvant chemo radiation and not discontinuous foci of tumor as indicated in the classic definition of TDs.
The presence of TDs was an independent adverse prognostic factor that was significantly associated with shorter disease-free survival independent of lymph node status in stage IV colorectal cancer patients who underwent simultaneous resection for synchronous colorectal liver metastases.
After chemo-radiotherapy, rectal cancer is usually associated with small clusters of tumor cells or isolated tumor cells, scattered within or outside the rectal wall which are often associated to fibrosis and chronic inflammation, as well as other radiation induced changes. The prognostic significance of TDs in rectal adenocarcinoma following neoadjuvant chemoradiation has not yet been determined, although this remains an important issue given that patients who receive neoadjuvant chemoradiation have more advanced tumors and the highest risk of distant and local recurrences.
TDs were associated with higher rates of lymph node involvement, distant metastases and reduced survival; more over TDs are associated with aggressive characteristics, including higher rates of positive circumferential resection margins.
- Conditions
- Cancer of Colon
- Medical subject headings
- Colonic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.
- Assessment of correlation between tumor deposits and clinicopathological characteristics of colorectal cancer.
- Detection of correlation between tumor deposits and stage of colorectal cancer.
- Correlation between tumor deposits and prognosis of colorectal cancer, clinicopathological characteristics of colorectal cancer, stage of colorectal cancer".
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2021
- Study startJun 2021 (estimated)
- Primary completionJan 2023 (estimated)
- Study completionApr 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cancer of ColonStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Naglaa Fathi Mosa, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04773626
- Sponsor's protocol ID
- Not yet
- Status last verified
- Mar 2021
- First submitted
- 24 Feb 2021
- Last updated
- 5 Mar 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Peparini N. Beyond T, N and M: The impact of tumor deposits on the staging and treatment of colorectal and gastric carcinoma. Surg Oncol. 2018 Jun;27(2):129-137. doi: 10.1016/j.suronc.2018.02.007. Epub 2018 Feb 21.
PubMed 29937162
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Role of Tumor Deposits on the Prognosis of Colorectal Carcinoma
- ClinicalTrials.gov ID
- NCT04773626
- Acronym / sponsor ID
- Not yet
- Conditions
- Cancer of Colon
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jun 2021 (estimated)
- Primary completion
- Jan 2023 (estimated)
- Study completion
- Apr 2023 (estimated)
- First posted
- 26 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Assessment of correlation between tumor deposits and clinicopathological characteristics of colorectal cancer.
- Detection of association between tumor deposits and stage of colorectal cancer.
- Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.
Detailed description
Colorectal cancer remains the third most common cancer and the third leading cause of cancer-related deaths. For colon cancer alone, 101,220 new cases were projected to occur in 2019, causing51,020 deaths.
A number of risk factors have been identified that influence susceptibility to colorectal cancer, including a family history, the presence of adenomatous polyps, inflammatory bowel disease (ulcerative colitis or Crohn's disease), and number of environmental factors of which diet is the most significant.
CRC differs from many other cancers in that diagnosis of the disease can be made earlier by screening techniques including colonoscopy. The progression of CRC is well established and begins with hyperproliferation of the colonic mucosa and adenoma formation and then adenocarcinomas that vary in metastatic potential.
The progression from normal intestinal epithelium to an invasive carcinoma is estimated to take 7-12 years. With the advent of early screening measures developed over the last few decades, CRC has become a preventable disease by treating patients with adenomatous polyps. Nearly 50% of patients diagnosed with CRC develop metastasis within five years. Most commonly these tumors metastasize to the liver and lungs but may be discovered in many other sites.
Despite significant improvements in both prevention and screening over the last twenty years, about 36,500 (36%) of such cases are still being diagnosed in stage III, with regional lymph node involvement (LN+, N1a-b, N2a-b) or tumor deposits (TD+, N1c).
Tumor deposits (TDs) or mesenteric tumor satellites were firs described in rectal carcinoma by Gabriel et al at St. Mark's Hospital in 1935. Subsequently, TDs have been detected in various malignancies other than colorectal carcinoma, including gastric, pancreatic, gallbladder, and bile duct carcinomas . Over the years, there is much debate about the genesis, histopathologic characteristics, and prognostic value of TDs.
TDs are associated with advanced colorectal carcinoma stage and poor prognosis, with variable outcome due to different definitions of TDs.
Before the 5th edition, published in 1997, TNM classification did not consider microscopic TDs to be lymph node metastases (LNMs), and they classified them as discontinuous extension in the T category .
In the 5th TNM edition the 3-mm rule was introduced, which stated that TDs >3mm in diameter were LNMs .
In the 6th edition published in 2002, TDs were classified based on the contour of the deposit. A TD with a smooth contour was considered as LMN, whereas a TD with an irregular contour was considered as venous invasion (V1/2) or lymphatic invasion (L1).
The 8th TNM Edition clarified that the presence of TDs does not change the primary tumor T category, but changes the node status (N) to pN1c if all regional lymph nodes are negative on pathological examination.
In studies of rectal cancer patients, it should be taken into account that TDs may indicate microscopic residuals of the main tumor after neoadjuvant chemo radiation and not discontinuous foci of tumor as indicated in the classic definition of TDs.
The presence of TDs was an independent adverse prognostic factor that was significantly associated with shorter disease-free survival independent of lymph node status in stage IV colorectal cancer patients who underwent simultaneous resection for synchronous colorectal liver metastases.
After chemo-radiotherapy, rectal cancer is usually associated with small clusters of tumor cells or isolated tumor cells, scattered within or outside the rectal wall which are often associated to fibrosis and chronic inflammation, as well as other radiation induced changes. The prognostic significance of TDs in rectal adenocarcinoma following neoadjuvant chemoradiation has not yet been determined, although this remains an important issue given that patients who receive neoadjuvant chemoradiation have more advanced tumors and the highest risk of distant and local recurrences.
TDs were associated with higher rates of lymph node involvement, distant metastases and reduced survival; more over TDs are associated with aggressive characteristics, including higher rates of positive circumferential resection margins.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- 1. This retrospective study includes primary invasive colorectal carcinoma samples from Egyptian patients that will be retrieved from the registry of Pathology department, South Egypt Cancer Institute and Assiut University Hospital. 2. All patients who underwent resection of colorectal cancer will be included in our study.
Key inclusion criteria (2 listed)
- 1-This retrospective study includes primary invasive colorectal carcinoma samples from Egyptian patients.
- 2-Patients who underwent resection of colorectal cancer will be included in our study.
Key exclusion criteria (1 listed)
- 1-All patients who underwent endoscopic biopsies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.
Time frame: 2 years
1. Assessment of correlation between tumor deposits and clinicopathological characteristics of colorectal cancer. 2. Detection of correlation between tumor deposits and stage of colorectal cancer. 3. Correlation between tumor deposits and prognosis of colorectal cancer, clinicopathological characteristics of colorectal cancer, stage of colorectal cancer".
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2021.
- Background: PubMed 29937162Peparini N. Beyond T, N and M: The impact of tumor deposits on the staging and treatment of colorectal and gastric carcinoma. Surg Oncol. 2018 Jun;27(2):129-137. doi: 10.1016/j.suronc.2018.02.007. Epub 2018 Feb 21.
Related trials for Cancer of Colon
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
RecruitingPhase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Colorectal Cancer Stage II, Colorectal Cancer Stage III
RecruitingPhase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer of Colon, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Naglaa Fathi, Master (0201096134165, naglaafathi600@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient. (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04773626, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2021.